NCT00844922View on ClinicalTrials.gov

Safety of Org 34517 900 mg in Patients Who Received Org 34517 in a Previous Trial (Study 28133/P05842)

PHASE2CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

June 30, 2006

Study Completion Date

June 30, 2006

Conditions
Depressive DisordersPsychotic DisordersDepression
Interventions
DRUG

SCH 900636

"Org 34517 300 mg on Day 1, 600 mg on Day 2, then 900 mg daily starting from Day 3. Subjects in this arm were also to continue the usual treatment for psychotic major depression."

DRUG

Placebo

Placebo

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00844922 - Safety of Org 34517 900 mg in Patients Who Received Org 34517 in a Previous Trial (Study 28133/P05842) | Biotech Hunter | Biotech Hunter